Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
41 hedge funds and large institutions have $12M invested in Soleno Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 5 closing their positions.
1,500% more call options, than puts
Call options by funds: $48K | Put options by funds: $3K
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more funds holding
Funds holding: 39 → 41 (+2)
1.82% more ownership
Funds ownership: 2.41% → 4.23% (+1.8%)
2% more capital invested
Capital invested by funds: $11.8M → $12M (+$189K)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$2.66M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.35M |
| 3 |
BC
Birchview Capital
Burlington,
Vermont
|
+$967K |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$621K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$584K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$113K |
| 2 |
Two Sigma Advisers
New York
|
-$52.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$42.1K |
| 4 |
Two Sigma Investments
New York
|
-$34.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$28K |
SLNO Hedge Fund Activity: Q1 2022 in Review
41 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2022, worth a combined $12M — up 1.6% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SLNO positions and 5 closed out — a net gain of 2 holders — while 9 added to existing stakes and 13 trimmed.
The largest buyer was Abingworth, adding an estimated $2.66M. The largest seller was Nantahala Capital Management, cutting an estimated $113K.
- 41 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2022, up from 39 in Q4 2021.
- Funds reported $12M of Soleno Therapeutics stock for Q1 2022, up 1.6% quarter-over-quarter.
- 7 funds opened new Soleno Therapeutics positions in Q1 2022 and 5 closed out, a net change of +2 holders.
- The largest Soleno Therapeutics buyer in Q1 2022 was Abingworth, an estimated $2.66M added.
- The largest Soleno Therapeutics seller in Q1 2022 was Nantahala Capital Management, an estimated $113K sold.
Based on aggregated 13F filings for Q1 2022.